Product Information
MEMANTINE HCL ER 21 MG CAPSULE is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.3563 per EA under NDC 69680016330. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on Oct 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
21 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680016330
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEMANTINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213985FDA Approved
10/11/2022
TE Code
AB
On Market Since
2/19/2024
Pharmacological Classes
Price Statistics
The NADAC for MEMANTINE HCL ER 21 MG CAPSULE has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 22.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3563 per EA |
|---|---|
| All-time high | $0.4738 (Apr 16, 2025) |
| All-time low | $0.3021 (Dec 17, 2025) |
| 52-week high | $0.3820 |
| 52-week low | $0.3021 |
| Median price | $0.3491 |
| Average price | $0.3657 |
| Largest weekly change | +9.8% (Sep 23, 2026) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
memantine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
N-methyl-D-aspartate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEMANTINE HCL ER 21 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEMANTINE HCL ER 21 MG CAPSULE, manufactured by Vitruvias Therapeutics Inc., is $0.3563 per EA (NDC 69680016330), effective Sep 30, 2026.
How has the price of MEMANTINE HCL ER 21 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEMANTINE HCL ER 21 MG CAPSULE has declined 22.1%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for MEMANTINE HCL ER 21 MG CAPSULE?
Since Mar 12, 2025, the NADAC for MEMANTINE HCL ER 21 MG CAPSULE has ranged from a low of $0.3021 (Dec 17, 2025) to a high of $0.4738 (Apr 16, 2025), with a median of $0.3491 per EA.
Are there cheaper alternatives to MEMANTINE HCL ER 21 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MEMANTINE HCL ER 21 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MEMANTINE HCL ER 21 MG CAPSULE?
MEMANTINE HCL ER 21 MG CAPSULE (NDC 69680016330) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.